慢性肾脏病患者中使用受体激动剂治疗2型糖尿病 - Suppr | 超能文献

文献检索
文档翻译
深度研究
学术资讯

Zotero 插件

邀请有礼
套餐&价格
历史记录

应用&插件

Zotero 插件浏览器插件 Mac 客户端 Windows 客户端微信小程序

定价

高级版会员购买积分包购买API积分包

服务

文献检索文档翻译深度研究 API 文档 MCP 服务

关于我们

关于 Suppr 公司介绍联系我们用户协议隐私条款

关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Treatment of Type 2 Diabetes With Receptor Agonists Among Patients With CKD.慢性肾脏病患者中使用受体激动剂治疗2型糖尿病

Kidney Int Rep. 2022 Sep 9;7(11):2323-2324. doi: 10.1016/j.ekir.2022.09.001. eCollection 2022 Nov.

2

SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.钠-葡萄糖协同转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病成人患者：临床实践指南。

BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.

3

Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.胰高血糖素样肽-1 受体激动剂与二肽基肽酶-4 抑制剂用于 2 型糖尿病合并晚期慢性肾脏病患者的死亡率相关。

JAMA Netw Open. 2022 Mar 1;5(3):e221169. doi: 10.1001/jamanetworkopen.2022.1169.

4

Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease.用于2型糖尿病和慢性肾脏病患者的肠促胰岛素疗法

J Clin Med. 2023 Dec 29;13(1):201. doi: 10.3390/jcm13010201.

5

Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.基于肠促胰岛素的疗法在慢性肾脏病合并2型糖尿病患者中的药代动力学及临床应用

Clin Pharmacokinet. 2015 Jan;54(1):1-21. doi: 10.1007/s40262-014-0198-2.

6

The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice.胰高血糖素样肽-1受体激动剂在2型糖尿病和慢性肾脏病中的潜力：从随机试验到临床实践

Ther Adv Endocrinol Metab. 2022 Jul 19;13:20420188221112490. doi: 10.1177/20420188221112490. eCollection 2022.

7

Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations.胰高血糖素样肽-1受体激动剂在2型糖尿病合并慢性肾脏病患者中的应用：关键证据及实际考量的叙述性综述

Diabetes Ther. 2022 Mar;13(3):389-421. doi: 10.1007/s13300-021-01198-5. Epub 2022 Feb 17.

8

Utilization of glucagon-like peptide-1 receptor agonists and changes in clinical characteristics in patients with type 2 diabetes by chronic kidney disease stage in Japan: A descriptive observational study using a nationwide electronic medical records database.利用日本全国性电子病历数据库对 2 型糖尿病患者进行描述性观察研究：根据慢性肾脏病分期分析胰高血糖素样肽-1 受体激动剂的利用情况和临床特征变化。

Diabetes Obes Metab. 2022 Mar;24(3):486-498. doi: 10.1111/dom.14600. Epub 2021 Dec 5.

9

Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease.钠-葡萄糖共转运蛋白 2 抑制剂与胰高血糖素样肽-1 受体激动剂在伴有 2 型糖尿病和轻度/中度慢性肾脏病患者中的疗效比较。

Diabetes Obes Metab. 2024 Apr;26(4):1273-1281. doi: 10.1111/dom.15427. Epub 2024 Jan 8.

10

Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD.糖尿病合并慢性肾脏病患者中钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽-1受体激动剂的使用及贫血情况

JAMA Netw Open. 2024 Mar 4;7(3):e240946. doi: 10.1001/jamanetworkopen.2024.0946.

引用本文的文献

1

Echoes of Dormancy: Anomic Aphasia Unveils Neurocysticercosis Reactivation in a Patient on Semaglutide.休眠的回声：一例使用司美格鲁肽患者的命名性失语揭示神经囊尾蚴病再激活

NeuroSci. 2025 May 5;6(2):40. doi: 10.3390/neurosci6020040.

本文引用的文献

1

Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: Analysis of the SUSTAIN and PIONEER Programs.胰高血糖素样肽-1受体激动剂司美格鲁肽降低糖化血红蛋白与基线估算肾小球滤过率无关：SUSTAIN和PIONEER项目分析

Kidney Int Rep. 2022 Aug 3;7(11):2345-2355. doi: 10.1016/j.ekir.2022.07.167. eCollection 2022 Nov.

2

Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease.度拉糖肽每周一次给药用于2型糖尿病合并2/3期慢性肾脏病患者的安全性和有效性

Diabetes Ther. 2020 Jul;11(7):1467-1480. doi: 10.1007/s13300-020-00815-z. Epub 2020 Apr 18.

3

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.

口服司美格鲁肽在伴有中度肾功能损害的 2 型糖尿病患者中的疗效和安全性（PIONEER 5）：一项安慰剂对照、随机、3a 期临床试验。

Lancet Diabetes Endocrinol. 2019 Jul;7(7):515-527. doi: 10.1016/S2213-8587(19)30192-5. Epub 2019 Jun 9.

4

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.度拉鲁肽对比甘精胰岛素治疗 2 型糖尿病合并中重度慢性肾脏病患者（AWARD-7）：一项多中心、开放标签、随机试验。

Lancet Diabetes Endocrinol. 2018 Aug;6(8):605-617. doi: 10.1016/S2213-8587(18)30104-9. Epub 2018 Jun 14.

慢性肾脏病患者中使用受体激动剂治疗2型糖尿病 - Suppr | 超能文献

Treatment of Type 2 Diabetes With Receptor Agonists Among Patients With CKD.

作者信息

Østergaard Jakob A, Cooper Mark E

机构信息

Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.

Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.

出版信息

Kidney Int Rep. 2022 Sep 9;7(11):2323-2324. doi: 10.1016/j.ekir.2022.09.001. eCollection 2022 Nov.

DOI:10.1016/j.ekir.2022.09.001

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9751839/

Abstract

摘要